GenesisCare Repairing COVID Disrupted Pathways in Breast Cancer Care With First Sunnyvale Women's Center

Sunnyvale, Texas, the only facility dedicated to multidisciplinary breast healthcare, utilizes advanced diagnostics to deliver personalized care and the best possible life outcomes.

GenesisCare—one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom—announced the opening of its new Sunnyvale Women's Center with patient-friendly facilities and an experienced clinical team to this new site to provide Dallas-area residents with end-to-end, multidisciplinary breast health care. The comprehensive patient-centered services available include mammography, diagnosis, treatment, and post-treatment follow-up. Patients will have rapid access to advanced and innovative technologies that deliver unprecedented accuracy, faster treatment sessions, and a reduced risk of side effects.

On average, 1 in 8 American women (13%) will develop breast cancer in their lifetime. In 2022, we will see approximately 287,8502 new cases of invasive breast cancer, along with 51,400 new noninvasive (in situ) breast cancer. The American Cancer Society ranked Texas as the second state in the nation for having the highest number of cases per capita, with an estimated 20,900 new cases of female breast cancer with 3420 deaths in 2021.

"The Sunnyvale Women's Center allows us to meet the need for effective, targeted diagnosis and treatment with easy, local access," shares Anita Tharian, DO, GenesisCare Medical Oncologist. "Bridging gaps in care is especially important as regular women's screening and care being disrupted by COVID across the Dallas area."

Read more.

Related Videos
Kathryn Lindley, MD, FACC
Dr Ajay Goel
Dr Ajay Goel
Julie Patterson, PharmD, PhD
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Screenshot of Fran Gregory, PharmD, MBA, during a video interview
Yael Mauer, MD, MPH
Pregnant Patient | image credit: pressmaster -
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
CH LogoCenter for Biosimilars Logo